MS
Therapeutic Areas
Fortress Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZYCUBO® (copper histidinate) | Menkes Disease | Approved/Commercial |
| Emrosi™ (Minocycline Hydrochloride ER Capsules, 40 mg) | Rosacea | Approved/Commercial |
| Qbrexza® | Primary Axillary Hyperhidrosis | Approved/Commercial |
| Targadox® (doxycycline hyclate) | Severe Acne | Approved/Commercial |
| UNLOXCYT™ (cosibelimab-ipdl) | Cutaneous Squamous Cell Carcinoma (cSCC) | Approved/Commercial |
| CUTX-101 | Menkes Disease | NDA/BLA Filed |
| CAEL-101 | Light Chain (AL) Amyloidosis | Phase 3 |
| BAER-101 (AZD7325) | CNS Disorders | Phase 2 |